Incidence increasing along with number of patients who are overweight or obese.
Associated with increased cardiovascular risk.
May cause acute pancreatitis when fasting levels >5.7 mmol/L (500 mg/dL).
Treatment includes lifestyle modification for all patients.
Statins are generally first-line pharmacotherapy in patients with triglycerides <5.69 mmol/L (<500 mg/dL) in the presence of ≥2 cardiac risk factors.
Fibric acid derivatives or fish oils are used as first-line therapy in those with triglycerides ≥5.69 mmol/L (≥500 mg/dL). They may be added to statins to achieve targets in patients with triglycerides <5.69 mmol/L (<500 mg/dL).
Hypertriglyceridaemia is defined by the National Cholesterol Education Program Adult Treatment Panel III as fasting plasma triglyceride level ≥2.3 mmol/L (≥200 mg/dL). Borderline high is defined as 150 to 199 mg/dL, high as 200 to 499 mg/dL, and very high as ≥500 mg/dL.   Chylomicronaemia is present when triglyceride level is ≥11.3 mmol/L (≥1000 mg/dL). Guidelines from several national and international medical organisations regarding the determination and treatment of hypertriglyceridaemia use different nomenclature, yet are similar in their recommendations.   
Professor of Medicine
Playa Vista Medical Center
DAL is an author of several references cited in this monograph.
Use of this content is subject to our disclaimer